PRESS RELEASE published on 03/11/2026 at 18:30, 6 months ago ATON: UPDATE ON THE ACTIVITIES OF ITS SUBSIDIARY INOVIEM SCIENTIFIC Aton Group's subsidiary, Inoviem Scientific, transforms drug development by prioritizing patient samples & AI technology, accelerating preclinical programs with high-value translational data AI Technology Drug Development Inoviem Scientific Aton Group Patient Sample
BRIEF published on 03/11/2026 at 18:20, 6 months ago Inoviem Scientific: Advances in Pharmaceutical Development Personalized Medicine Pharmaceutical Development Translational Pharmacology Inoviem Scientific Integrated Platform
BRIEF published on 03/11/2026 at 18:20, 6 months ago Inoviem Scientific : Avancées dans le Développement Pharmaceutique Médecine Personnalisée Développement Pharmaceutique Pharmacologie Translationnelle Inoviem Scientific Plateforme Intégrée
PRESS RELEASE published on 03/11/2026 at 18:15, 6 months ago ATON : POINT D'AVANCEMENT SUR L'ACTIVITÉ DE LA FILIALE INOVIEM SCIENTIFIC Le Groupe Aton via sa filiale Inoviem Scientific innove dans le développement de médicaments en utilisant des échantillons de patients pour des analyses moléculaires assistées par IA Médecine Personnalisée Développement Pharmaceutique Groupe Aton Innovation Thérapeutique Inoviem Scientific
BRIEF published on 02/18/2026 at 18:35, 6 months 21 days ago Hadrien Lanvin nommé Directeur général délégué du Groupe Aton Biotechnologie Nomination Sciences De La Vie Groupe Aton Hadrien Lanvin
BRIEF published on 02/18/2026 at 18:35, 6 months 21 days ago Hadrien Lanvin nommé directeur général adjoint du groupe Aton Biotechnologie Croissance Stratégique Directeur Général Adjoint Groupe Aton Hadrien Lanvin
BRIEF published on 02/18/2026 at 18:35, 6 months 21 days ago Hadrien Lanvin appointed Deputy Managing Director of the Aton Group Biotechnology Life Sciences Appointment Hadrien Lanvin Aton Group
BRIEF published on 02/18/2026 at 18:35, 6 months 21 days ago Hadrien Lanvin Appointed Deputy CEO of Aton Group Biotechnology Strategic Growth Deputy CEO Hadrien Lanvin Aton Group
PRESS RELEASE published on 02/18/2026 at 18:30, 6 months 21 days ago ATON APPOINTS HADRIEN LANVIN AS DEPUTY CEO Aton Group appoints Hadrien Lanvin as Deputy CEO to drive value and visibility, strengthening leadership and strategic positioning. Focus on maximizing asset portfolio valuation and accelerating development Valuation Leadership Deputy CEO Hadrien Lanvin Aton Group
PRESS RELEASE published on 02/18/2026 at 18:30, 6 months 21 days ago ATON ANNONCE LA NOMINATION DE HADRIEN LANVIN AU POSTE DE DIRECTEUR GÉNÉRAL DÉLÉGUÉ Le Groupe Aton nomme Hadrien Lanvin au poste de Directeur général délégué, renforçant ainsi son équipe de direction. Prochaine publication sur Inoviem Scientific et la recherche préclinique Aton Biotechnologies Sciences Médicales Inoviem Scientific Hadrien Lanvin
Published on 09/12/2026 at 02:35, 11 hours 13 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 48 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 43 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 23 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 48 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 18 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 33 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 38 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 3 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 33 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
